CD14+S100A9+ monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 10, 2012, Pages 1025-1036

  Feng, Po Hao ^a   Lee, Kang Yun ^a,b   Chang, Ya Ling ^a   Chan, Yao Fei ^a   Kuo, Lu Wei ^a   Lin, Ting Yu ^a   Chung, Fu Tsai ^a   Kuo, Chih Shi ^a   Yu, Chih Teng ^a   Lin, Shu Min ^a   Wang, Chun Hua ^a   Chou, Chun Liang ^a   Huang, Chien Da ^a   Kuo, Han Pin ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Cancer immunity; Myeloid derived suppressor cell; Non small cell lung cancer; S100A9

Indexed keywords

ARGINASE; CALGRANULIN B; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CISPLATIN; DOCETAXEL; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 4 RECEPTOR ALPHA; PEMETREXED;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FUNCTIONAL STATUS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MYELOID DERIVED SUPPRESSOR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; TUMOR IMMUNITY;

ANTIGENS, CD11B; ANTIGENS, CD14; ANTINEOPLASTIC AGENTS; ARGINASE; CALGRANULIN B; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CISPLATIN; COCULTURE TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-13; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYELOID CELLS; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; RECEPTORS, INTERLEUKIN-4;

EID: 84869223841     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201204-0636OC     Document Type: Article

References (38)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
2. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-296. (Pubitemid 46697910)
3. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the nkp30 receptor. Hepatology 2009;50:799-807.
4. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-4506.
5. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-174.
6. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 2009;182:240-249.
7. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010;184:3106-3116.
8. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008;111:4233-4244.
9. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006;116:2777-2790. (Pubitemid 44511641)
10. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, et al. Arginaseproducing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-3048. (Pubitemid 40524582)
11. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, et al. Population alterations of L-arginase and inducible nitric oxide synthase-expressed CD11b(+)/cd14 (-)/cd15 (+)/cd33 (+) myeloid-derived suppressor cells and CD8 (+) t lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010;136:35-45.
12. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, et al. IL4ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009;182:6562-6568.
13. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005;5:641-654. (Pubitemid 41113195)
14. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. GR-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced t regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006;66:1123-1131. (Pubitemid 43165981)
15. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are STAT3HI and overexpress CD80, CD83, and DC-sign. Cancer Res 2010;70:4335-4345.
16. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, Greten TF, Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+) CD25(+)Foxp3(+) T cells. Gastroenterology 2008;135:234-243. (Pubitemid 351899008)
17. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007;25:2546-2553. (Pubitemid 47041228)
18. Bronte V, Cingarlini S, Marigo I, De Santo C, Gallina G, Dolcetti L, Ugel S, Peranzoni E, Mandruzzato S, Zanovello P. Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol Invest 2006;35:327-357. (Pubitemid 44266779)
19. Condamine T, Gabrilovich DI.Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011;32:19-25.
20. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory s100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008;181:4666-4675.
21. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by s100a9 protein. J Exp Med 2008;205:2235-2249.
22. Lee KY, Ho SC, Chan YF, Wang CH, Huang CD, Liu WT, Lin SM, Lo YL, Chang YL, Kuo LW, et al. Reduced NF-kappab repressing factor: a link toward systemic inflammation in COPD. Eur Respir J 2012;40:863-873.
23. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100a8/a9 activate key genes and pathways in colon tumor progression. Molecular Cancer Research 2011;9:133-148.
24. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008;222:180-191. (Pubitemid 351430370)
25. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J, Ochoa AC. Arginase 1 in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J ExpMed 2005;202:931-939. (Pubitemid 41396893)
26. Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, et al. Bone marrow myeloid-derived suppressor cells (MDSCS) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010;116:5738-5747.
27. Hart KM, Byrne KT, Molloy MJ, Usherwood EM, Berwin B. Il-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol 2011;2:29.
28. Akdis CA, Joss A, Akdis M, Faith A, Blaser K. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 2000;14:1666-1668.
29. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous toll-like receptor 4 agonist s100a8/s100a9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009;86:557-566.
30. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, et al. Rage signaling sustains inflammation and promotes tumor development. J Exp Med 2008;205:275-285. (Pubitemid 351281593)
31. Chung FT, Lee KY, Wang CW, Heh CC, Chan YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, et al. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer 2012;131:E227-E235.
32. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149-163.
33. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89:381-410.
34. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappab ligand pathway. Cancer Res 2005;65:11001-11009. (Pubitemid 41713370)
35. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clinical Cancer Research 2000;6:2104-2119. (Pubitemid 30305111)
36. Ohbayashi M, Yasuda M, Kawakami I, Kohyama N, Kobayashi Y, Yamamoto T. Effect of interleukins response to ECM-induced acquisition of drug resistance in MCF-7 cells. Exp Oncol 2008;30:276-282.
37. Pour L, Svachova H, Adam Z, Mikulkova Z, Buresova L, Kovarova L, Buchler T, Penka M, Vorlicek J, Hajek R. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 2010;57:29-34.
38. Wang R, Zhang J, Chen S, Lu M, Luo X, Yao S, Liu S, Qin Y, Chen H. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer 2011;74:188-196.